WallStreetZenWallStreetZen

NASDAQ: CRMD
Cormedix Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CRMD

Based on 5 analysts offering 12 month price targets for Cormedix Inc.
Min Forecast
$9.00+56.25%
Avg Forecast
$12.60+118.75%
Max Forecast
$19.00+229.86%

Should I buy or sell CRMD stock?

Based on 5 analysts offering ratings for Cormedix Inc.
Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CRMD stock forecasts and price targets.

CRMD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-26
lockedlocked$00.00+00.00%2024-08-15
lockedlocked$00.00+00.00%2024-08-15
lockedlocked$00.00+00.00%2024-07-25
lockedlocked$00.00+00.00%2024-04-09

1 of 1

Forecast return on equity

Is CRMD forecast to generate an efficient return?
Company
N/A
Industry
-116.41%
Market
54.93%

Forecast return on assets

Is CRMD forecast to generate an efficient return on assets?
Company
N/A
Industry
24.04%

CRMD earnings per share forecast

What is CRMD's earnings per share in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.58
Avg 2 year Forecast
$0.17

CRMD revenue forecast

What is CRMD's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$29.4M+3,545.86%
Avg 2 year Forecast
$100.2M+12,331.17%
CRMD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRMD revenue growth forecast

How is CRMD forecast to perform vs Biotechnology companies and vs the US market?
Company
1,014.95%
Industry
53.36%
Market
8.2%
CRMD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRMD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRMD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRMD$5.76$12.60+118.75%Strong Buy
NAUT$2.55$4.50+76.47%Buy
XOMA$27.28$78.50+187.76%Buy
KYTX$7.34$20.00+172.48%Buy
OCGN$1.14$6.00+426.32%Strong Buy
View Top Biotech Stocks

Cormedix Stock Forecast FAQ

Is Cormedix Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: CRMD) stock is to Strong Buy CRMD stock.

Out of 5 analysts, 2 (40%) are recommending CRMD as a Strong Buy, 3 (60%) are recommending CRMD as a Buy, 0 (0%) are recommending CRMD as a Hold, 0 (0%) are recommending CRMD as a Sell, and 0 (0%) are recommending CRMD as a Strong Sell.

If you're new to stock investing, here's how to buy Cormedix stock.

What is CRMD's earnings growth forecast for 2024-2025?

(NASDAQ: CRMD) Cormedix's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.33%.

Cormedix's earnings in 2024 is -$53,115,995.On average, 1 Wall Street analyst forecast CRMD's earnings for 2024 to be -$32,398,779, with the lowest CRMD earnings forecast at -$32,398,779, and the highest CRMD earnings forecast at -$32,398,779.

In 2025, CRMD is forecast to generate $9,496,194 in earnings, with the lowest earnings forecast at $9,496,194 and the highest earnings forecast at $9,496,194.

What is CRMD's revenue growth forecast for 2024-2025?

(NASDAQ: CRMD) Cormedix's forecast annual revenue growth rate of 1,014.95% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 53.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 8.2%.

Cormedix's revenue in 2024 is $806,119.On average, 1 Wall Street analysts forecast CRMD's revenue for 2024 to be $1,641,724,342, with the lowest CRMD revenue forecast at $1,641,724,342, and the highest CRMD revenue forecast at $1,641,724,342.

In 2025, CRMD is forecast to generate $5,597,726,992 in revenue, with the lowest revenue forecast at $5,597,726,992 and the highest revenue forecast at $5,597,726,992.

What is CRMD's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: CRMD) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 24.04%.

What is CRMD's Price Target?

According to 5 Wall Street analysts that have issued a 1 year CRMD price target, the average CRMD price target is $12.60, with the highest CRMD stock price forecast at $19.00 and the lowest CRMD stock price forecast at $9.00.

On average, Wall Street analysts predict that Cormedix's share price could reach $12.60 by Aug 26, 2025. The average Cormedix stock price prediction forecasts a potential upside of 118.75% from the current CRMD share price of $5.76.

What is CRMD's Earnings Per Share (EPS) forecast for 2024-2025?

(NASDAQ: CRMD) Cormedix's current Earnings Per Share (EPS) is -$0.93. On average, analysts forecast that CRMD's EPS will be -$0.58 for 2024, with the lowest EPS forecast at -$0.58, and the highest EPS forecast at -$0.58. In 2025, CRMD's EPS is forecast to hit $0.17 (min: $0.17, max: $0.17).

What is CRMD's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: CRMD) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.